KR20200135826A - 리게리주맙을 사용하여 만성 자발성 두드러기를 치료하는 방법 - Google Patents

리게리주맙을 사용하여 만성 자발성 두드러기를 치료하는 방법 Download PDF

Info

Publication number
KR20200135826A
KR20200135826A KR1020207030057A KR20207030057A KR20200135826A KR 20200135826 A KR20200135826 A KR 20200135826A KR 1020207030057 A KR1020207030057 A KR 1020207030057A KR 20207030057 A KR20207030057 A KR 20207030057A KR 20200135826 A KR20200135826 A KR 20200135826A
Authority
KR
South Korea
Prior art keywords
dose
antibody
ige
binding fragment
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207030057A
Other languages
English (en)
Korean (ko)
Inventor
토마스 세베린
필립 로우
라인홀드 마틴 자노차
스테판 쾨네-보스
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20200135826A publication Critical patent/KR20200135826A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020207030057A 2018-03-26 2019-03-25 리게리주맙을 사용하여 만성 자발성 두드러기를 치료하는 방법 Ceased KR20200135826A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862647928P 2018-03-26 2018-03-26
US62/647,928 2018-03-26
US201962811800P 2019-02-28 2019-02-28
US62/811,800 2019-02-28
PCT/IB2019/052408 WO2019186369A1 (en) 2018-03-26 2019-03-25 Methods of treating chronic spontaneous urticaria using ligelizumab

Publications (1)

Publication Number Publication Date
KR20200135826A true KR20200135826A (ko) 2020-12-03

Family

ID=66476672

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207030057A Ceased KR20200135826A (ko) 2018-03-26 2019-03-25 리게리주맙을 사용하여 만성 자발성 두드러기를 치료하는 방법

Country Status (9)

Country Link
US (2) US20210115155A1 (https=)
EP (1) EP3773904A1 (https=)
JP (1) JP7589045B2 (https=)
KR (1) KR20200135826A (https=)
CN (1) CN112203724A (https=)
AU (1) AU2019244666A1 (https=)
CA (1) CA3094749A1 (https=)
IL (1) IL277474B2 (https=)
WO (1) WO2019186369A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250533A1 (en) * 2020-06-09 2021-12-16 Novartis Ag Methods of treatment using omalizumab or ligelizumab
WO2021250546A1 (en) 2020-06-09 2021-12-16 University Of Washington Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria
CA3220757A1 (en) * 2021-06-14 2022-12-22 Novartis Ag Pharmaceutical formulation containing an anti-ige antibody
EP4384553A1 (en) * 2021-08-13 2024-06-19 Genentech, Inc. Dosing for anti-tryptase antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds
SI2000481T1 (sl) * 2003-02-01 2016-08-31 Tanox, Inc. Anti-humana protitelesa IgE z visoko afiniteto
CN1798575A (zh) * 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
EP1718669A4 (en) * 2004-02-02 2007-10-10 Tanox Inc IDENTIFICATION OF NEW IGE EPITOPES
US20130005708A1 (en) * 2011-06-29 2013-01-03 Lalwani Dinusha N Histamine antagonist treatment of inflammatory skin disorders
TW201343176A (zh) * 2012-04-16 2013-11-01 Novartis Ag 使用ｉｌ－１７拮抗劑治療乾癬性關節炎之方法
CN104547325A (zh) * 2015-01-21 2015-04-29 李健 一种治疗慢性特发性荨麻疹的药物组合物及其应用

Also Published As

Publication number Publication date
JP2021523881A (ja) 2021-09-09
JP7589045B2 (ja) 2024-11-25
US20210115155A1 (en) 2021-04-22
EP3773904A1 (en) 2021-02-17
US20250026858A1 (en) 2025-01-23
WO2019186369A1 (en) 2019-10-03
RU2020134794A (ru) 2022-04-26
IL277474B1 (en) 2025-12-01
IL277474B2 (en) 2026-04-01
IL277474A (en) 2020-11-30
CA3094749A1 (en) 2019-10-03
RU2020134794A3 (https=) 2022-04-26
AU2019244666A1 (en) 2020-10-08
CN112203724A (zh) 2021-01-08

Similar Documents

Publication Publication Date Title
EP3757126B1 (en) Methods of treating psoriatic arthritis using il-17 antagonists
RU2749512C2 (ru) Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента
US20250026858A1 (en) Methods of treating chronic spontaneous urticaria using ligelizumab
JP2025106377A (ja) Ｉｌ－１７アンタゴニストを用いて化膿性汗腺炎を治療すること
KR20170096187A (ko) Pvns를 치료하기 위한 항-csf1r 항체
US20230235069A1 (en) Treatment of atopic dermatitis
CN119095617A (zh) 用于治疗患有头皮斑块型银屑病的受试者的方法
US20220112294A1 (en) Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies
IL291807A (en) Dosing regimens for treating or preventing c5-associated diseases
RU2783540C2 (ru) Способы лечения хронической спонтанной крапивницы с применением лигелизумаба
KR20250039391A (ko) 다초점성 운동신경병증(mmn) 치료를 위한 투여 용법
CA3062179A1 (en) Methods of selectively treating asthma using il-17 antagonists
US20260078175A1 (en) Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
KR20220110512A (ko) 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법
CN118488851A (zh) 特应性皮炎的治疗
RU2806304C1 (ru) Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента
WO2025259719A1 (en) Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease
HK40035240B (en) Methods of treating psoriatic arthritis using il-17 antagonists
HK1229257B (en) Methods of treating ankylosing spondylitis using anti-il-17 antibodies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601